Alpha Cognition (XCNQ:ACOG) Equity-to-Asset : -1.92 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alpha Cognition's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$-6.32 Mil. Alpha Cognition's Total Assets for the quarter that ended in Dec. 2023 was C$3.29 Mil.

The historical rank and industry rank for Alpha Cognition's Equity-to-Asset or its related term are showing as below:

XCNQ:ACOG' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.92 Med: -0.22 Max: 0.7
Current: -1.92

During the past 4 years, the highest Equity to Asset Ratio of Alpha Cognition was 0.70. The lowest was -1.92. And the median was -0.22.

XCNQ:ACOG's Equity-to-Asset is ranked worse than
93.94% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs XCNQ:ACOG: -1.92

Alpha Cognition Equity-to-Asset Historical Data

The historical data trend for Alpha Cognition's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Equity-to-Asset Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.70

-0.45

-1.92

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial									-0.45	0.29	-0.25	-3.61	-1.92

Competitive Comparison of Alpha Cognition's Equity-to-Asset

For the Biotechnology subindustry, Alpha Cognition's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Cognition's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's Equity-to-Asset falls into.

Alpha Cognition Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Alpha Cognition's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-6.323	/	3.29
	=

Alpha Cognition's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-6.323	/	3.29
	=

Alpha Cognition (XCNQ:ACOG) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Alpha Cognition Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (XCNQ:ACOG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (XCNQ:ACOG) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

ACOGF:USA

Address

301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2

Website

https://www.alphacognition.com

Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.

Alpha Cognition (XCNQ:ACOG) Headlines

No Headlines